[HTML][HTML] Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a …
S Shapiro, F Torres, J Feldman, A Keogh, M Allard… - Respiratory …, 2017 - Elsevier
Objective Pulmonary arterial hypertension (PAH) is a condition which may lead to right
ventricular failure and premature death. While recent data supports the initial combination of …
ventricular failure and premature death. While recent data supports the initial combination of …
[PDF][PDF] Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a …
S Shapiro, F Torres, J Feldman, A Keogh… - Respiratory …, 2017 - academia.edu
abstract Objective: Pulmonary arterial hypertension (PAH) is a condition which may lead to
right ventricular failure and premature death. While recent data supports the initial …
right ventricular failure and premature death. While recent data supports the initial …
Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a …
S Shapiro, F Torres, J Feldman… - Respiratory …, 2017 - utsouthwestern.elsevierpure.com
Objective Pulmonary arterial hypertension (PAH) is a condition which may lead to right
ventricular failure and premature death. While recent data supports the initial combination of …
ventricular failure and premature death. While recent data supports the initial combination of …
[HTML][HTML] Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a …
S Shapiro, F Torres, J Feldman, A Keogh… - Respiratory …, 2017 - resmedjournal.com
Objective Pulmonary arterial hypertension (PAH) is a condition which may lead to right
ventricular failure and premature death. While recent data supports the initial combination of …
ventricular failure and premature death. While recent data supports the initial combination of …
Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a …
S Shapiro, F Torres, J Feldman, A Keogh, M Allard… - Respiratory …, 2017 - infona.pl
Pulmonary arterial hypertension (PAH) is a condition which may lead to right ventricular
failure and premature death. While recent data supports the initial combination of …
failure and premature death. While recent data supports the initial combination of …
Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a …
S Shapiro, F Torres, J Feldman, A Keogh… - Respiratory …, 2017 - europepmc.org
Objective Pulmonary arterial hypertension (PAH) is a condition which may lead to right
ventricular failure and premature death. While recent data supports the initial combination of …
ventricular failure and premature death. While recent data supports the initial combination of …
Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a …
S Shapiro, F Torres, J Feldman… - Respiratory …, 2017 - pubmed.ncbi.nlm.nih.gov
Objective Pulmonary arterial hypertension (PAH) is a condition which may lead to right
ventricular failure and premature death. While recent data supports the initial combination of …
ventricular failure and premature death. While recent data supports the initial combination of …
[引用][C] Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a …
S Shapiro, F Torres, J Feldman, A Keogh, M Allard… - Respiratory …, 2017 - cir.nii.ac.jp
Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i
therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic …
therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic …